CLINICAL USEFULNESS OF APOMORPHINE IN MOVEMENT-DISORDERS

被引:61
作者
COLOSIMO, C [1 ]
MERELLO, M [1 ]
ALBANESE, A [1 ]
机构
[1] FLENI, BUENOS AIRES, ARGENTINA
关键词
APOMORPHINE; DOPAMINE; DYSTONIA; HUNTINGTONS DISEASE; LEVODOPA; LISURIDE; PARKINSONS DISEASE;
D O I
10.1097/00002826-199406000-00004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Apomorphine, the first dopamine agonist to be synthesized, has received a renewed interest in the last few years. This compound acts powerfully on D-1 and D-2 dopamine receptors and has the most complete pharmacological profile of all clinically available dopamine agonists. When given subcutaneously, apomorphine consistently reverses levodopa-resistant ''off'' periods in parkinsonian subjects: thus, it is used in cases with severe motor fluctuations, either by continuous infusion with a portable pump or by multiple injections. Studies based on this approach have been highly encouraging, as they have shown a significant reduction in off time and a good drug tolerability. The main side effect has been the occurrence of nodular skin lesions, especially when continuous infusions were used. At variance with other dopamine agonists, a low incidence of psychiatric morbidity has been reported with apomorphine. The few available comparative reports have shown that this compound is more potent and better tolerated than lisuride. Parenteral apomorphine has been used in Parkinson's disease (PD) to replace levodopa after surgery or to treat the malignant syndrome brought about by sudden levodopa withdrawal. Acute challenge with apomorphine has been used to test dopaminergic responsiveness in parkinsonian syndromes and in dystonia. The clinical response to apomorphine may predict the effect of a chronic therapy with levodopa in similar to 90% of PD cases. Further studies are still necessary to evaluate the exact relationship between the acute response to apomorphine and a chronic therapy. In addition, apomorphine has been used to conduct clinical pharmacological studies in PD, for it is particularly well suited for research on the pharmacodynamics of central dopamine receptors. In summary, apomorphine appears to be an efficacious and safe drug for the treatment of advanced PD. It must still be considered under clinical evaluation as a test drug for acute challenge in PD and dystonia. Finally, in our opinion, the available data suggest apomorphine (in conjunction with domperidone) as a first-choice treatment for the neuroleptic malignant syndrome and the temporary replacement of levodopa (e.g., after gastrointestinal surgery).
引用
收藏
页码:243 / 259
页数:17
相关论文
共 84 条
[1]   NEUROLEPTIC MALIGNANT SYNDROME [J].
ABBOTT, RJ ;
LOIZOU, LA .
BRITISH JOURNAL OF PSYCHIATRY, 1986, 148 :47-51
[2]   BROMOCRIPTINE ASSOCIATED WITH A PERIPHERAL DOPAMINE BLOCKING-AGENT IN TREATMENT OF PARKINSONS-DISEASE [J].
AGID, Y ;
BONNET, AM ;
POLLAK, P ;
SIGNORET, JL ;
LHERMITTE, F .
LANCET, 1979, 1 (8116) :570-572
[3]  
ALBANESE A, 1986, J NEURAL TRANSM, P3
[4]  
Albanese A, 1991, Funct Neurol, V6, P269
[5]   EVIDENCE FOR DOPAMINE RECEPTOR STIMULATION BY APOMORPHINE [J].
ANDEN, NE ;
RUBENSON, A ;
FUXE, K ;
HOKFELT, T .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1967, 19 (09) :627-&
[6]  
BALDESSARINI RJ, 1981, APOMORPHINE OTHER DO, V1, P219
[7]   SUBCUTANEOUS APOMORPHINE AS A DIAGNOSTIC-TEST FOR DOPAMINERGIC RESPONSIVENESS IN PARKINSONIAN SYNDROMES [J].
BARKER, R ;
DUNCAN, J ;
LEES, A .
LANCET, 1989, 1 (8639) :675-675
[8]  
Bentivoglio A.R., 1992, MOV DISORD S, V7, P180
[9]   NALOXONE PARTLY COUNTERACTS APOMORPHINE SIDE-EFFECTS [J].
BONUCCELLI, U ;
PICCINI, P ;
DELDOTTO, P ;
ROSSI, G ;
CORSINI, GU ;
MURATORIO, A .
CLINICAL NEUROPHARMACOLOGY, 1991, 14 (05) :442-449
[10]   APOMORPHINE IN MALIGNANT SYNDROME DUE TO LEVODOPA WITHDRAWAL [J].
BONUCCELLI, U ;
PICCINI, P ;
CORSINI, GU ;
MURATORIO, A .
ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1992, 13 (02) :169-170